BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27399377)

  • 1. Diffusion Weighted Magnetic Resonance Imaging Radiophenotypes and Associated Molecular Pathways in Glioblastoma.
    Zinn PO; Hatami M; Youssef E; Thomas GA; Luedi MM; Singh SK; Colen RR
    Neurosurgery; 2016 Aug; 63 Suppl 1():127-135. PubMed ID: 27399377
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme.
    Heiland DH; Simon-Gabriel CP; Demerath T; Haaker G; Pfeifer D; Kellner E; Kiselev VG; Staszewski O; Urbach H; Weyerbrock A; Mader I
    Sci Rep; 2017 Mar; 7():43523. PubMed ID: 28266556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
    Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
    J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
    Czarnek N; Clark K; Peters KB; Mazurowski MA
    J Neurooncol; 2017 Mar; 132(1):55-62. PubMed ID: 28074320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma.
    Kondo M; Uchiyama Y
    J Neuroradiol; 2018 Jul; 45(4):236-241. PubMed ID: 29274693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
    Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
    Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine-learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time.
    Liao X; Cai B; Tian B; Luo Y; Song W; Li Y
    J Cell Mol Med; 2019 Jun; 23(6):4375-4385. PubMed ID: 31001929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
    Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis.
    Cho HR; Jeon H; Park CK; Park SH; Choi SH
    Sci Rep; 2018 Oct; 8(1):16022. PubMed ID: 30375429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative radiogenomic analysis for multicentric radiophenotype in glioblastoma.
    Kong DS; Kim J; Lee IH; Kim ST; Seol HJ; Lee JI; Park WY; Ryu G; Wang Z; Ma'ayan A; Nam DH
    Oncotarget; 2016 Mar; 7(10):11526-38. PubMed ID: 26863628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
    Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models.
    Zinn PO; Singh SK; Kotrotsou A; Hassan I; Thomas G; Luedi MM; Elakkad A; Elshafeey N; Idris T; Mosley J; Gumin J; Fuller GN; de Groot JF; Baladandayuthapani V; Sulman EP; Kumar AJ; Sawaya R; Lang FF; Piwnica-Worms D; Colen RR
    Clin Cancer Res; 2018 Dec; 24(24):6288-6299. PubMed ID: 30054278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of Semi-Automated Segmentations in Glioblastoma.
    Huber T; Alber G; Bette S; Boeckh-Behrens T; Gempt J; Ringel F; Alberts E; Zimmer C; Bauer JS
    Clin Neuroradiol; 2017 Jun; 27(2):153-161. PubMed ID: 26490369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma multiforme versus solitary supratentorial brain metastasis: differentiation based on morphology and magnetic resonance signal characteristics.
    Maurer MH; Synowitz M; Badakshi H; Lohkamp LN; Wüstefeld J; Schäfer ML; Wiener E
    Rofo; 2013 Mar; 185(3):235-40. PubMed ID: 23196836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI.
    Park JE; Kim HS; Jo Y; Yoo RE; Choi SH; Nam SJ; Kim JH
    Sci Rep; 2020 Mar; 10(1):4250. PubMed ID: 32144360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death.
    Colen RR; Wang J; Singh SK; Gutman DA; Zinn PO
    Radiology; 2015 Apr; 275(1):215-27. PubMed ID: 25490189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
    Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
    Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
    Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.